CClinicalTrials.gg
Not yet recruitingNCT07816614Updated Sep 15, 2026

The Effect of Mandala Coloring on Quality of Life in Cancer Patients

An interventional study of Mandala Coloring in Cancer and Neoplasms (Cancer / Tumors), sponsored by Emine TARLABELEN KARAYTUĞ. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Emine TARLABELEN KARAYTUĞ · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to determine the effect of mandala coloring on the quality of life in cancer patients. Conducting a quasi-experimental design with a pretest-posttest control group, the study will involve a total of 76 cancer patients hospitalized in an oncology ward. Participants will be assigned to either the experimental (mandala) group or the control group. At the baseline, data will be collected face-to-face using a Patient Information Form and the EORTC QLQ-C30 Version 3.0 Quality of Life Scale. Patients in the experimental group will be provided with a mandala coloring book and colored pencils, and they will practice mandala coloring for 30 minutes, at least twice a week, over a 3-week period. The control group will receive routine clinical care with no intervention. After 3 weeks, the EORTC QLQ-C30 scale will be re-administered to both groups to evaluate and compare changes in their quality of life.

02

Conditions studied

  • Cancer
  • Neoplasms (Cancer / Tumors)

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed with cancer
  • Aged 18 years and older
  • Voluntarily willing to participate in the study
  • Able to hold and use a pencil for coloring

Exclusion criteria

Exclusion Criteria:

  • Refusing to participate or withdraws consent before the study begins
  • Unable to comply regularly with the scheduled mandala coloring program
  • Incapable of using a pencil due to physical or cognitive impairments
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Mandala Coloring Intervention

    Patients in this group will be provided with a mandala coloring book and 12 colored pencils. They will practice mandala coloring for 30 minutes, at least twice a week, over a 3-week period in addition to routine clinical care.

    Behavioral: Mandala Coloring

  • No intervention
    Standard Care

    Patients in this group will receive only routine clinical care during the 3-week study period and will not perform any mandala coloring activity.

Interventions

  • BehavioralMandala Coloring

    Patients in the experimental group will be provided with a mandala coloring book and a set of 12 colored pencils. They will be requested to practice mandala coloring in a quiet, distraction-free environment for 30 minutes, at least twice a week, for a total duration of 3 weeks. The intervention will be conducted in addition to routine clinical care.

    Also known as: Experimental Group

05

What researchers measure

Primary outcomes

  1. Quality of Life Score via EORTC QLQ-C30

    Quality of life will be evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Version 3.0. The questionnaire includes 30 items. All raw scores are linearly transformed into a standard scale ranging from 0 to 100. For the global health and functional scales, a higher score indicates a better quality of life. For the symptom scales, a higher score indicates a worse outcome.

    Time frame: Baseline and 3 weeks

06

Study locations

1 site
  • Aydın Adnan Menderes University Hospital
    Aydin, Turkey (Türkiye)
07

Registry details

Key details

Study ID
NCT07816614
Lead sponsor
Emine TARLABELEN KARAYTUĞ
Collaborators
The Scientific and Technological Research Council of Turkey
Responsible party
Emine TARLABELEN KARAYTUĞ (Research Assistant, PhD, Aydin Adnan Menderes University) — Sponsor-investigator
First posted
Sep 11, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Emine Tarlabelen Karaytug, Research Assistant, PhD
Contact
emine.karaytug@adu.edu.tr
+90-531-384-2926

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion